Monopar Therapeutics Q1 2026 net loss $3.9M; NDA on track for mid-2026

Monopar Therapeutics

Net loss $3.9M ($0.46/share) in Q1 2026 vs $2.6M ($0.38/share) in Q1 2025.
Cash equivalents and investments $137.5M; expects funding through Dec 2027.
NDA for ALXN1840 (Wilson disease) on track for FDA submission in mid-2026.
R&D expenses $3.49M, up $1.84M YoY due to contractor/consulting and personnel.
Presented at AAN; upcoming at EAN (June 27-30) and EASL Congress (May 27-30).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.